Abstract:CRISPR-Cas systems are widely used for genome engineering technologies, and in their natural setting, they play crucial roles in bacterial and archaeal adaptive immunity, protecting against phages and other mobile genetic elements. Previously we discovered bacteriophage-encoded Cas9-specific anti-CRISPR (Acr) proteins that serve as countermeasures against host bacterial immunity by inactivating their CRISPR-Cas systems 1 . We hypothesized that the evolutionary advantages conferred by anti-CRISPRs would drive the widespread occurrence of these proteins in nature 2–4 . We have identified new anti-CRISPRs using the bioinformatic approach that successfully identified previous Acr proteins 1 against Neisseria meningitidis Cas9 (NmeCas9). In this work we report two novel anti-CRISPR families in strains of Haemophilus parainfluenzae and Simonsiella muelleri , both of which harbor type II-C CRISPR-Cas systems 5 . We characterize the type II-C Cas9 orthologs from H. parainfluenzae and S. muelleri , show that the newly identified Acrs are able to inhibit these systems, and define important features of their inhibitory mechanisms. The S. muelleri Acr is the most potent NmeCas9 inhibitor identified to date. Although inhibition of NmeCas9 by anti-CRISPRs from H. parainfluenzae and S. muelleri reveals cross-species inhibitory activity, more distantly related type II-C Cas9s are not inhibited by these proteins. The specificities of anti-CRISPRs and divergent Cas9s appear to reflect co-evolution of their strategies to combat or evade each other. Finally, we validate these new anti-CRISPR proteins as potent off-switches for Cas9 genome engineering applications.

Cell-specific CRISPR/Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins

Cell-specific CRISPR–Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

A Versatile Anti-CRISPR Platform for Opto- and Chemogenetic Control of CRISPR-Cas9 and Cas12 across a Wide Range of Orthologs

Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.

Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing

Disabling Cas9 by an anti-CRISPR DNA mimic

A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy

Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing

Engineering Anti‐CRISPR Proteins to Create CRISPR‐Cas Protein Switches for Activatable Genome Editing and Viral Protease Detection

Engineering Anti‐CRISPR Proteins to Create Cas12a Protein Switches for Activatable Genome Editing and Viral Protease Detection

Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications

A Broad-Spectrum Inhibitor of CRISPR-Cas9

Computational design of anti-CRISPR proteins with improved inhibition potency and expanded specificity

Potent Cas9 inhibition in bacterial and human cells by new anti-CRISPR protein families

Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering

Programmable RNA targeting with the single-protein CRISPR effector Cas7-11

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in Streptomyces

Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system

Proteasomal control of anti-CRISPRs for the regulation of CRISPR/Cas9 activity using Cas9-ACROBAT